Dennis Fenton Sells Shares of TRAX
Dennis Fenton sold 6,030 shares of TRAX on June 15, marking notable insider activity.
Key Points
- Dennis Fenton sold 6,030 shares of TRAX on June 15, 2026, while the stock traded at $18.17.
- TRAX saw insider buying activity on the same day from John Schmid, Magda Marquet, Anthony Ware, and Rita Jain.
- Analysts from Wells Fargo, Piper Sandler, and others have initiated buy ratings with targets up to $54.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Dennis Fenton, an insider at TRAX, sold 6,030 shares on June 15, 2026. The stock was trading at $18.17 at the time of the transaction. This move was part of a series of insider activities on the same day.
Insider Buying and Selling at First Tracks Biotherapeutics, Inc.
On June 15, 2026, several insiders were active in TRAX's stock. John Schmid, Magda Marquet, Anthony Ware, and Rita Jain each purchased 6,030 shares, while Jain acquired 7,330 shares. Meanwhile, John Orwin and Dennis Fenton sold 6,030 shares each. None of these transactions were planned under a Rule 10b5-1 plan.
Analysts Set New Price Targets
Analysts are optimistic about TRAX's prospects. On June 8, 2026, Wells Fargo initiated coverage with a buy rating and a $30 price target. Piper Sandler followed on May 4 with a buy rating and a $54 target. Other firms like HC Wainwright & Co., Leerink Partners, and JP Morgan have also initiated buy ratings, with targets ranging from $30 to $46.
Bottom Line
Insider trading activity at TRAX on June 15, 2026, shows both buying and selling, reflecting diverse perspectives among insiders. Analysts are generally bullish, with several firms initiating buy ratings and setting price targets well above the current trading price. This insider and analyst activity provides valuable insights, though it is backward-looking and may not reflect current positions or opinions.
Get First Tracks Biotherapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TRAX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.